Schwarz R, Hofmann B, Gergs U, Neumann J
Naunyn Schmiedebergs Arch Pharmacol. 2025; .
PMID: 39907786
DOI: 10.1007/s00210-025-03854-0.
Neumann J, Hofmann B, Gergs U
Heliyon. 2019; 5(8):e02197.
PMID: 31406941
PMC: 6684494.
DOI: 10.1016/j.heliyon.2019.e02197.
Br J Pharmacol. 2008; 110(Suppl):81P-184P.
PMID: 19108271
PMC: 2175557.
DOI: 10.1111/j.1476-5381.1993.tb16292.x.
Gergs U, Boknik P, Schmitz W, Simm A, Silber R, Neumann J
Naunyn Schmiedebergs Arch Pharmacol. 2008; 379(5):533-40.
PMID: 19037631
DOI: 10.1007/s00210-008-0374-8.
Neumann J, Boknik P, Matherne G, Lankford A, Schmitz W
Br J Pharmacol. 2003; 138(1):209-17.
PMID: 12522092
PMC: 1573638.
DOI: 10.1038/sj.bjp.0705012.
Functional studies in atrium overexpressing A1-adenosine receptors.
Neumann J, Vahlensieck U, Boknik P, Linck B, Luss H, Muller F
Br J Pharmacol. 1999; 128(7):1623-9.
PMID: 10602345
PMC: 1571796.
DOI: 10.1038/sj.bjp.0702963.
Studies of the nucleoside transporter inhibitor, draflazine, in the human myocardium.
Bohm M, Weinhold C, Schwinger R, Muller-Ehmsen J, Bohm D, Reichenspurner H
Br J Pharmacol. 1994; 112(1):137-42.
PMID: 8032635
PMC: 1910273.
DOI: 10.1111/j.1476-5381.1994.tb13043.x.
Increased sensitivity to alpha-adrenoceptor stimulation but intact purinergic and muscarinergic effects in prehypertensive cardiac hypertrophy of spontaneously hypertensive rats.
Bohm M, Mende U, Schmitz W, Scholz H
Naunyn Schmiedebergs Arch Pharmacol. 1986; 333(3):284-9.
PMID: 3020440
DOI: 10.1007/BF00512942.
Pharmacological characterization of A1 adenosine receptors in isolated rat ventricular myocytes.
Martens D, Lohse M, Rauch B, Schwabe U
Naunyn Schmiedebergs Arch Pharmacol. 1987; 336(3):342-8.
PMID: 2825048
DOI: 10.1007/BF00172688.
Selective updates on mechanisms of action of positive inotropic agents.
GRUPP G
Mol Cell Biochem. 1987; 76(2):97-112.
PMID: 2823098
DOI: 10.1007/BF00223475.
Functional role of cholinoceptors and purinoceptors in human isolated atrial and ventricular heart muscle.
Jakob H, Oelert H, Rupp J, Nawrath H
Br J Pharmacol. 1989; 97(4):1199-208.
PMID: 2790382
PMC: 1854632.
DOI: 10.1111/j.1476-5381.1989.tb12579.x.
Inotropic response to DPI 201-106 in the failing human heart.
Bohm M, Diet F, KEMKES B, Wankerl M, Erdmann E
Br J Pharmacol. 1989; 98(1):275-83.
PMID: 2553190
PMC: 1854676.
DOI: 10.1111/j.1476-5381.1989.tb16892.x.
Adenosine inhibits the positive inotropic effect of 3-isobutyl-1-methylxanthine in papillary muscles without effect on cyclic AMP or cyclic GMP.
Bohm M, Bruckner R, Neumann J, Nose M, Schmitz W, Scholz H
Br J Pharmacol. 1988; 93(4):729-38.
PMID: 2455577
PMC: 1853904.
DOI: 10.1111/j.1476-5381.1988.tb11456.x.
[Cardiac effects of adenosine. Mechanism of action, pathophysiologic and clinical significance].
Bohm M
Klin Wochenschr. 1987; 65(11):487-99.
PMID: 2441109
DOI: 10.1007/BF01721034.
Antagonism of novel inotropic agents at A1 adenosine receptors and m-cholinoceptors in human myocardium.
Ungerer M, Bohm M, Schwinger R, Erdmann E
Naunyn Schmiedebergs Arch Pharmacol. 1990; 341(6):577-85.
PMID: 2392160
DOI: 10.1007/BF00171739.
Different negative inotropic activity of Ca2(+)-antagonists in human myocardial tissue.
Schwinger R, Bohm M, Erdmann E
Klin Wochenschr. 1990; 68(16):797-805.
PMID: 2145465
DOI: 10.1007/BF01796269.
[Alterations of the cAMP-adenylate cyclase system in the failing human heart. Consequences for the therapy with inotropic drugs].
Bohm M, Schwinger R, Erdmann E
Klin Wochenschr. 1990; 68(18):887-95.
PMID: 1979643
DOI: 10.1007/BF01649033.